TrialBritish journal of cancer2007

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.

S C Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.